Orchestra BioMed Holdings, Inc.

Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) is a biomedical innovation company focused on developing and commercializing therapies for cardiovascular and cardiometabolic diseases, including its lead BackBeat Cardiac Neuromodulation Therapy platform. The company went public through a business combination with Health Assurance Acquisition Corp, a healthcare-focused SPAC that completed its IPO in 2020 and was sponsored by Health Assurance Management LLC. The August 2022 Form 10-Q filing, bearing accession number 0001213900-22-047919, reflects Orchestra BioMed's status as it advanced through the de-SPAC process within the medical device and biomedical sector. Sign up at SpacDesk for full filing history, sponsor profiles, and real-time deal tracking on OBIO and hundreds of other SPAC transactions.